The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A member of the class of quinazolines that is quinazoline substituted by (5-chloro-2H-1,3-benzodioxol-4-yl)amino, (oxan-4-yl)oxy and 2-(4-methylpiperazin-1-yl)ethoxy groups at positions 4, 5 and 7, respectively. It is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively). Saracatinib was originally developed by AstraZeneca for the treatment of cancer but in 2019 it was granted orphan drug designation by the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs.
saracatinib results in decreased activity of CSK protein saracatinib inhibits the reaction [CSK protein results in decreased expression of CYP7A1 mRNA]
saracatinib inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]; saracatinib inhibits the reaction [lithocholic acid acetate results in increased expression of CYP24A1 mRNA]
saracatinib results in increased expression of CYP7A1 mRNA saracatinib inhibits the reaction [Calcitriol results in decreased expression of CYP7A1 mRNA]; saracatinib inhibits the reaction [CSK protein results in decreased expression of CYP7A1 mRNA]; saracatinib inhibits the reaction [lithocholic acid acetate results in decreased expression of CYP7A1 mRNA]
saracatinib inhibits the reaction [Calcitriol results in increased phosphorylation of VDR protein]; saracatinib inhibits the reaction [lithocholic acid acetate results in increased phosphorylation of VDR protein]